Impact of the COVID‐19 pandemic on stage and incidence of head and neck cancer: A rapid review and meta‐analysis

Abstract

AbstractObjectivesThis rapid review aims to evaluate the impact of the COVID‐19 pandemic on incidence of head and neck cancer (HNC) and stage distribution at diagnosis.DesignRapid review and meta‐analysis.ParticipantsComparative data for new HNC patients between a pre‐pandemic cohort (before March 2020) and a pandemic cohort (after March 2020 during the lockdown period).Main Outcomes MeasuredData on tumour stage, incidence, referral pathway (number of new patient referrals), or workload levels (number of HNC treatments). Data on stage were summarised as odds ratios (OR) with 95% confidence intervals (CI), and data related to changes in numbers of diagnoses, referrals, and workload levels were summarised as a narrative synthesis.ResultsA total of 31 reports were included in this review. Individually 16 out of 23 studies did not show a significant impact on stage relative to the pre‐pandemic period. However, the meta‐analysis revealed that patients diagnosed with HNC during the pandemic were 16% more likely to have nodal involvement (OR = 1.16; 95% CI 1.00–1.35), 17% more likely to have a late overall stage (OR = 1.17; 95% CI 1.01–1.36), and 32% more likely to present with advanced tumour extent (T3 and T4 stage) (OR = 1.32; 95% CI 1.08–1.62). Data on incidence was extremely limited and not currently sufficient to assess trends in burden of disease.ConclusionsThis review indicates that during the COVID‐19 pandemic, there was upstaging of HNC at diagnosis, suggesting the provision of care to HNC patients was significantly affected.